News BMS' Opdivo still streets ahead of Merck rival BMS to refocus operations, according to Q3 results.
News NICE rejects Keytruda in lung cancer, points to price and da... Cancer immunotherapy too expensive.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
